210 related articles for article (PubMed ID: 8257443)
41. Induction of the plasminogen activator system by mechanical stimulation of human bronchial epithelial cells.
Chu EK; Cheng J; Foley JS; Mecham BH; Owen CA; Haley KJ; Mariani TJ; Kohane IS; Tschumperlin DJ; Drazen JM
Am J Respir Cell Mol Biol; 2006 Dec; 35(6):628-38. PubMed ID: 16794260
[TBL] [Abstract][Full Text] [Related]
42. Urokinase induces expression of its own receptor in Beas2B lung epithelial cells.
Shetty S; Idell S
J Biol Chem; 2001 Jul; 276(27):24549-56. PubMed ID: 11342540
[TBL] [Abstract][Full Text] [Related]
43. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
[TBL] [Abstract][Full Text] [Related]
44. Biotin-Chasing Assay to Evaluate uPAR Stability and Cleavage on the Surface of Cells.
Leksa V; Schiller HB; Stockinger H
Methods Mol Biol; 2018; 1731():39-47. PubMed ID: 29318541
[TBL] [Abstract][Full Text] [Related]
45. Binding and activation of plasminogen on the surface of osteosarcoma cells.
Campbell PG; Wines K; Yanosick TB; Novak JF
J Cell Physiol; 1994 Apr; 159(1):1-10. PubMed ID: 7511144
[TBL] [Abstract][Full Text] [Related]
46. Activation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro.
Lacroix R; Sabatier F; Mialhe A; Basire A; Pannell R; Borghi H; Robert S; Lamy E; Plawinski L; Camoin-Jau L; Gurewich V; Angles-Cano E; Dignat-George F
Blood; 2007 Oct; 110(7):2432-9. PubMed ID: 17606760
[TBL] [Abstract][Full Text] [Related]
47. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.
Conese M; Blasi F
Biol Chem Hoppe Seyler; 1995 Mar; 376(3):143-55. PubMed ID: 7612191
[TBL] [Abstract][Full Text] [Related]
48. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
[TBL] [Abstract][Full Text] [Related]
49. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
[TBL] [Abstract][Full Text] [Related]
50. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
Wells JM; Strickland S
J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
[TBL] [Abstract][Full Text] [Related]
51. Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation.
Poliakov A; Tkachuk V; Ovchinnikova T; Potapenko N; Bagryantsev S; Stepanova V
Biochem J; 2001 May; 355(Pt 3):639-45. PubMed ID: 11311125
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
53. The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
Friess H; Duarte R; Kleeff J; Fukuda A; Tang WH; Graber H; Schilling M; Zimmermann A; Korc M; Büchler MW
Surgery; 1998 Jul; 124(1):79-86. PubMed ID: 9663255
[TBL] [Abstract][Full Text] [Related]
54. Regulation of macrophage receptor-bound plasmin by autoproteolysis.
Falcone DJ; Borth W; McCaffrey TA; Mathew J; McAdam K
J Biol Chem; 1994 Dec; 269(51):32660-6. PubMed ID: 7528219
[TBL] [Abstract][Full Text] [Related]
55. Characterization of the cellular binding site for the urokinase-type plasminogen activator.
Estreicher A; Wohlwend A; Belin D; Schleuning WD; Vassalli JD
J Biol Chem; 1989 Jan; 264(2):1180-9. PubMed ID: 2536017
[TBL] [Abstract][Full Text] [Related]
56. Interferons and retinoids enhance and dexamethasone suppresses urokinase-mediated plasminogen activation in promyelocytic leukemia cells.
Mustjoki S; Tapiovaara H; Sirén V; Vaheri A
Leukemia; 1998 Feb; 12(2):164-74. PubMed ID: 9519778
[TBL] [Abstract][Full Text] [Related]
57. A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration.
McNeill H; Jensen PJ
Cell Regul; 1990 Oct; 1(11):843-52. PubMed ID: 1965151
[TBL] [Abstract][Full Text] [Related]
58. Binding of single-chain prourokinase to the urokinase receptor of human U937 cells.
Cubellis MV; Nolli ML; Cassani G; Blasi F
J Biol Chem; 1986 Dec; 261(34):15819-22. PubMed ID: 3023326
[TBL] [Abstract][Full Text] [Related]
59. Pro-urokinase-type plasminogen activator is a substrate for hepsin.
Moran P; Li W; Fan B; Vij R; Eigenbrot C; Kirchhofer D
J Biol Chem; 2006 Oct; 281(41):30439-46. PubMed ID: 16908524
[TBL] [Abstract][Full Text] [Related]
60. Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence.
Liang OD; Chavakis T; Linder M; Bdeir K; Kuo A; Preissner KT
Biol Chem; 2003 Feb; 384(2):229-36. PubMed ID: 12675515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
